|
1
|
Kleppe M, Wang T, Van Gorp T, Slangen BF,
Kruse AJ and Kruitwagen RF: Lymph node metastasis in stages I and
II ovarian cancer: A review. Gynecol Oncol. 123:610–614. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pakneshan S, Safarpour D, Tavassoli F and
Jabbari B: Brain metastasis from ovarian cancer: A systematic
review. J Neurooncol. 119:1–6. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ottevanger PB: Ovarian cancer stem cells
more questions than answers. Semin Cancer Biol. 44:67–71. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Crosbie EJ, Flaum N, Harkness EF, Clayton
RD, Holland C, Martin-Hirsch P, Wood N, Keating P, Woodward ER,
Lalloo F, et al: Specialist oncological surgery for removal of the
ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant
carriers may reduce primary peritoneal cancer risk to very low
levels. Int J Cancer. 148:1155–1163. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zheng H and Gao YN: Primary debulking
surgery or neoadjuvant chemotherapy followed by interval debulking
surgery for patients with advanced ovarian cancer. Chin J Cancer
Res. 24:304–309. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ducoulombier S, Golfier F, Colomban O,
Benayoun D, Bolze PA, Tod M and You B: Modeling CA-125 during
neoadjuvant chemotherapy for predicting optimal cytoreduction and
relapse risk in ovarian cancer. Anticancer Res. 37:6879–6886.
2017.PubMed/NCBI
|
|
7
|
Wang Y, Herrstedt J, Havsteen H, DePoint
Christensen R, Mirza MR, Lund B, Maenpaa J and Kristensen G: A
multicenter, non-randomized, phase II study of docetaxel and
carboplatin administered every 3 weeks as second line chemotherapy
in patients with first relapse of platinum sensitive epithelial
ovarian, peritoneal or fallopian tube cancer. BMC Cancer.
14:9372014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang B, Chen F, Xu Q, Han L, Xu J, Gao L,
Sun X, Li Y, Li Y, Qian M and Sun Y: Revisiting ovarian cancer
microenvironment: A friend or a foe? Protein Cell. 9:674–692. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Luo Q, Wu T, Wu W, Chen G, Luo X, Jiang L,
Tao H, Rong M, Kang S and Deng M: The functional role of
voltage-gated sodium channel Nav1.5 in metastatic breast cancer.
Front Pharmacol. 11:11112020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang W, Wang J, Yan H, Zhang K and Liu Y:
Upregulation of USP11 promotes epithelialtomesenchymal transition
by deubiquitinating Snail in ovarian cancer. Oncol Rep.
41:1739–1748. 2019.PubMed/NCBI
|
|
11
|
Dai G, Sun B, Gong T, Pan Z, Meng Q and Ju
W: Ginsenoside Rb2 inhibits epithelial-mesenchymal transition of
colorectal cancer cells by suppressing TGF-beta/Smad signaling.
Phytomedicine. 56:126–135. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Oh E, Hong J and Yun CO: Regulatory T
cells induce metastasis by increasing Tgf-β and enhancing the
epithelial-mesenchymal transition. Cells. 8:13872019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
van Schaijik B, Davis PF, Wickremesekera
AC, Tan ST and Itinteang T: Subcellular localisation of the stem
cell markers OCT4, SOX2, NANOG, KLF4 and c-MYC in cancer: A review.
J Clin Pathol. 71:88–91. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fu W, Lei C, Yu Y, Liu S, Li T, Lin F, Fan
X, Shen Y, Ding M, Tang Y, et al: EGFR/Notch antagonists enhance
the response to inhibitors of the PI3K-Akt pathway by decreasing
tumor-initiating cell frequency. Clin Cancer Res. 25:2835–2847.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hu S, Fu W, Li T, Yuan Q, Wang F, Lv G, Lv
Y, Fan X, Shen Y, Lin F, et al: Antagonism of EGFR and Notch limits
resistance to EGFR inhibitors and radiation by decreasing
tumor-initiating cell frequency. Sci Transl Med. 9:eaag03392017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Morel AP, Lievre M, Thomas C, Hinkal G,
Ansieau S and Puisieux A: Generation of breast cancer stem cells
through epithelial-mesenchymal transition. PLoS One. 3:e28882008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Q, Yu C, Yue C and Liu X:
Fusobacterium nucleatum produces cancer stem cell characteristics
via EMT-resembling variations. Int J Clin Exp Pathol. 13:1819–1828.
2020.PubMed/NCBI
|
|
19
|
Čipak Gašparović A, Milković L, Dandachi
N, Stanzer S, Pezdirc I, Vrančić J, Šitić S, Suppan C and Balic M:
Chronic oxidative stress promotes molecular changes associated with
epithelial mesenchymal transition, NRF2, and breast cancer stem
cell phenotype. Antioxidants (Basel). 8:6332019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Navas T, Kinders RJ, Lawrence SM,
Ferry-Galow KV, Borgel S, Hollingshead MG, Srivastava AK, Alcoser
SY, Makhlouf HR, Chuaqui R, et al: Clinical evolution of
epithelial-mesenchymal transition in human carcinomas. Cancer Res.
80:304–318. 2020.PubMed/NCBI
|
|
21
|
Hoca M, Becer E, Kabadayi H, Yucecan S and
Vatansever HS: The effect of resveratrol and quercetin on
epithelial-mesenchymal transition in pancreatic cancer stem cell.
Nutr Cancer. 72:1231–1242. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhou JM, Hu SQ, Jiang H, Chen YL, Feng JH,
Chen ZQ and Wen KM: OCT4B1 promoted EMT and regulated the
self-renewal of CSCs in CRC: Effects associated with the balance of
miR-8064/PLK1. Mol Ther Oncolytics. 15:7–20. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kenda Suster N and Virant-Klun I: Presence
and role of stem cells in ovarian cancer. World J Stem Cells.
11:383–397. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao Y, He M, Cui L, Gao M, Zhang M, Yue
F, Shi T, Yang X, Pan Y, Zheng X, et al: Chemotherapy exacerbates
ovarian cancer cell migration and cancer stem cell-like
characteristics through GLI1. Br J Cancer. 122:1638–1648. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Song L, Chen X, Mi L, Liu C, Zhu S, Yang
T, Luo X, Zhang Q, Lu H and Liang X: Icariin-induced inhibition of
SIRT6/NF-κB triggers redox mediated apoptosis and enhances
anti-tumor immunity in triple-negative breast cancer. Cancer Sci.
111:4242–4256. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang C, Wang J, Chen K, Pang H, Li X, Zhu
J, Ma Y, Qiu T, Li W, Xie J and Zhang J: Caprylic acid (C8:0)
promotes bone metastasis of prostate cancer by dysregulated
adipo-osteogenic balance in bone marrow. Cancer Sci. 111:3600–3612.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zeng A, Liang X, Zhu S, Liu C, Luo X,
Zhang Q and Song L: Baicalin, a potent inhibitor of NF-κB signaling
pathway, enhances chemosensitivity of breast cancer cells to
docetaxel and inhibits tumor growth and metastasis both in vitro
and in vivo. Front Pharmacol. 11:8792020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang X, Ruan Q, Zhai Y, Lu D, Li C, Fu Y,
Zheng Z, Song Y and Guo J: Baicalein inhibits non-small-cell lung
cancer invasion and metastasis by reducing ezrin tension in
inflammation microenvironment. Cancer Sci. 111:3802–3812. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cui Y, Chen LJ, Huang T, Ying JQ and Li J:
The pharmacology, toxicology and therapeutic potential of
anthraquinone derivative emodin. Chin J Nat Med. 18:425–435.
2020.PubMed/NCBI
|
|
30
|
Li Q, Gao J, Pang X, Chen A and Wang Y:
Molecular mechanisms of action of emodin: As an anti-cardiovascular
disease drug. Front Pharmacol. 11:5596072020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Luo N, Fang J, Wei L, Sahebkar A, Little
PJ, Xu S, Luo C and Li G: Emodin in atherosclerosis prevention:
Pharmacological actions and therapeutic potential. Eur J Pharmacol.
890:1736172020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang Y, Zhang M, Hu G, Zhang Z and Song
R: Elevated system exposures of baicalin after combinatory oral
administration of rhein and baicalin: Mainly related to breast
cancer resistance protein (ABCG2), not
UDP-glucuronosyltransferases. J Ethnopharmacol. 250:1125282020.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shrimali D, Shanmugam MK, Kumar AP, Zhang
J, Tan BK, Ahn KS and Sethi G: Targeted abrogation of diverse
signal transduction cascades by emodin for the treatment of
inflammatory disorders and cancer. Cancer Lett. 341:139–149. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Song K, Lv T, Chen Y, Diao Y, Yao Q and
Wang Y: Emodin inhibits TGF-β2 by activating the FOXD3/miR199a axis
in ovarian cancer cells in vitro. Oncol Rep. 39:2063–2070.
2018.PubMed/NCBI
|
|
35
|
Dhamija S and Diederichs S: From junk to
master regulators of invasion: lncRNA functions in migration, EMT
and metastasis. Int J Cancer. 139:269–280. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Caspa Gokulan R and Devaraj H: Stem cell
markers CXCR-4 and CD133 predict aggressive phenotype and their
double positivity indicates poor prognosis of oral squamous cell
carcinoma. Cancers (Basel). 13:58952021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu HL, Tang HT, Yang HL, Deng TT, Xu YP,
Xu SQ, Peng L, Wang Z, Fang Q, Kuang XY and Li QS: Oct4 regulates
the transition of cancer stem-like cells to tumor endothelial-like
cells in human liver cancer. Front Cell Dev Biol. 8:5633162020.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lopez de Andres J, Grinan-Lison C, Jimenez
G and Marchal JA: Cancer stem cell secretome in the tumor
microenvironment: A key point for an effective personalized cancer
treatment. J Hematol Oncol. 13:1362020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xu J, Su Q, Gao M, Liang Q, Li J and Chen
X: Differential expression and effects of Peroxiredoxin-6 on drug
resistance and cancer stem cell-like properties in non-small cell
lung cancer. Onco Targets Ther. 12:10477–10486. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
He QZ, Luo XZ, Wang K, Zhou Q, Ao H, Yang
Y, Li SX, Li Y, Zhu HT and Duan T: Isolation and characterization
of cancer stem cells from high-grade serous ovarian carcinomas.
Cell Physiol Biochem. 33:173–184. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Huang R, Zhu L and Zhang Y: XIST lost
induces ovarian cancer stem cells to acquire taxol resistance via a
KMT2C-dependent way. Cancer Cell Int. 20:4362020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang W, Gao Y, Hai J, Yang J and Duan S:
HER2 decreases drug sensitivity of ovarian cancer cells via
inducing stem cell-like property in an NFκB-dependent way. Biosci
Rep. 39:BSR201808292019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Corrado G, Salutari V, Palluzzi E,
Distefano MG, Scambia G and Ferrandina G: Optimizing treatment in
recurrent epithelial ovarian cancer. Expert Rev Anticancer Ther.
17:1147–1158. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Karadimitris A, Chaidos A, Caputo V,
Goudevenou K, Ponnusamy K and Xiao X: Myeloma propagating cells,
drug resistance and relapse. Stem Cells. 33:3205–3211. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Clarke MF: Clinical and therapeutic
implications of cancer stem cells. N Engl J Med. 380:2237–2245.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Saxena K, Jolly MK and Balamurugan K:
Hypoxia, partial EMT and collective migration: Emerging culprits in
metastasis. Transl Oncol. 13:1008452020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
He L, Wang C, Zhang Y, Guo C, Wan Y and Li
Y: Effect of emodin on hyperlipidemia and hepatic lipid metabolism
in zebrafish larvae fed a high-cholesterol diet. Chem Biodivers.
e202100675. 2021.doi: 10.1002/cbdv.202100675 (Epub ahead of print).
View Article : Google Scholar
|
|
48
|
Horvat M, Avbelj M, Duran-Alonso MB,
Banjanac M, Petkovic H and Iskra J: Antiviral activities of
halogenated emodin derivatives against human coronavirus NL63.
Molecules. 26:68252021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhou Y, Wu R, Cai FF, Zhou WJ, Lu YY,
Zhang H, Chen QL, Sun MY and Su SB: Development of a novel
anti-liver fibrosis formula with luteolin, licochalcone A,
aloe-emodin and acacetin by network pharmacology and
transcriptomics analysis. Pharm Biol. 59:1594–1606. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Gao R, Wu X, Huang Z, Wang B, Li F, Xu H
and Ran L: Anti-tumor effect of aloe-emodin on cervical cancer
cells was associated with human papillomavirus E6/E7 and glucose
metabolism. Onco Targets Ther. 12:3713–3721. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Liu Q, Hodge J, Wang J, Wang Y, Wang L,
Singh U, Li Y, Yao Y, Wang D, Ai W, et al: Emodin reduces breast
cancer lung metastasis by suppressing Macrophage-induced breast
cancer cell Epithelial-mesenchymal transition and cancer stem cell
formation. Theranostics. 10:8365–8381. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Tong H, Huang Z, Chen H, Zhou B, Liao Y
and Wang Z: Emodin reverses gemcitabine resistance of pancreatic
cancer cell lines through inhibition of IKKβ/NF-κB signaling
pathway. Onco Targets Ther. 13:9839–9848. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Li N, Wang C, Zhang P and You S: Emodin
inhibits pancreatic cancer EMT and invasion by upregulating
microRNA1271. Mol Med Rep. 18:3366–3374. 2018.PubMed/NCBI
|
|
54
|
Gu J, Cui CF, Yang L, Wang L and Jiang XH:
Emodin inhibits colon cancer cell invasion and migration by
suppressing epithelial-mesenchymal transition via the
Wnt/beta-catenin pathway. Oncol Res. 27:193–202. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Dai G, Ding K, Cao Q, Xu T, He F, Liu S
and Ju W: Emodin suppresses growth and invasion of colorectal
cancer cells by inhibiting VEGFR2. Eur J Pharmacol. 859:1725252019.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Liu SC, Huang CM, Bamodu OA, Lin CS, Liu
BL, Tzeng YM, Tsai JT, Lee WH and Chen TM: Ovatodiolide suppresses
nasopharyngeal cancer by targeting stem cell-like population,
inducing apoptosis, inhibiting EMT and dysregulating JAK/STAT
signaling pathway. Phytomedicine. 56:269–278. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Tanabe S, Quader S, Cabral H and Ono R:
Interplay of EMT and CSC in cancer and the potential therapeutic
strategies. Front Pharmacol. 11:9042020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Luo Z, Wang Q, Lau WB, Lau B, Xu L, Zhao
L, Yang H, Feng M, Xuan Y, Yang Y, et al: Tumor microenvironment:
The culprit for ovarian cancer metastasis? Cancer Lett.
377:174–182. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Bockhorn M, Jain RK and Munn LL: Active
versus passive mechanisms in metastasis: Do cancer cells crawl into
vessels, or are they pushed? Lancet Oncol. 8:444–448. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Nowicki A, Kulus M, Wieczorkiewicz M,
Pieńkowski W, Stefańska K, Skupin-Mrugalska P, Bryl R, Mozdziak P,
Kempisty B and Piotrowska-Kempisty H: Ovarian cancer and cancer
stem cells-cellular and molecular characteristics, signaling
pathways, and usefulness as a diagnostic tool in medicine and
oncology. Cancers (Basel). 13:41782021. View Article : Google Scholar : PubMed/NCBI
|
